Cutting-edge early detection.
To increase testing compliance by decreasing discomfort.
Currently, there is no immediate diagnosis or combined diagnosis-treatment option for gynecologic malignancies such as cervical cancer. This leaves patients vulnerable to greater health risks, including infertility, and the potential of other aggressive types of gynecologic cancers. On a yearly basis there are 7.2 million new cases of cancer of the female reproductive system, of which up to 266,000 result in deaths.
A microneedle mediated diagnostic patch that detects early onset of cervical cancer, replacing invasive procedures such as the Pap Smear and Cytology. The digitized medical device, is able to detect novel targets within 30-45 min. - equivalent to a clinical visit. Providing benefits to health professionals for better management of guidelines and improved patient outcomes.
dermadiagnostics is committed to reducing the incidence of cervical cancer by increasing testing compliance through a non-invasive diagnostic patch. Our patient-centric products deliver accurate, same-day results while reducing diagnostic costs for healthcare providers.
Meet the dermadiagnostics team!
diapatch™ screens and detects —
Novel HPV strains
CIN II biomarkers
CIN III biomarkers
Seamless and effortless integration into busy, modern lifestyles, allowing for streamlined, higher quality patient care
and noninvasive diagnosis
Faster, more accurate diagnosis
Non-invasive approach for easier workflow and patient care
Same-day results for appropriate patient triaging, follow-up procedures, and treatment options
222 W Merchandise Mart Plaza #1230, Chicago, IL 60654
1400 East Angela Blvd.
South Bend, IN 46617
Our Phone No.